This multi-center, double-blind, randomized and placebo-controlled clinical trial compares the safety and efficacy of prulifloxacin versus placebo in adult travelers suffering acute bacterial gastroenteritis. Clinical trial sites included locations in the US, Mexico and Peru. The primary endpoint is time-to-last-unformed-stool. Secondary endpoints include clinical cure based on relief of symptoms and microbiological eradication rates.
Michael Chang, CEO and president of Optimer, said: “Completing patient enrollment for this first trial is an important milestone in Optimer’s prulifloxacin development program.”